Human CDON/CDO/CDON1 ORF/cDNA clone-Lentivirus plasmid (NM_001243597)

Cat. No.: pGMLP-SPh-080
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human CDON/CDO/CDON1 Lentiviral expression plasmid for CDON lentivirus packaging, CDON lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.

Our GM-Lentiviral vector is seamlessly integrated with the GM lentivirus packaging system. Discover more about the GM lentivirus packaging system.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to CDON/CDO products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Total Price: $1845.6
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMLP-SPh-080
Gene Name CDON
Accession Number NM_001243597
Gene ID 50937
Species Human
Product Type Lentivirus plasmid (overexpression)
Insert Length 3864 bp
Gene Alias CDO,CDON1,HPE11,ORCAM
Fluorescent Reporter ZsGreen
Mammalian Cell Selection Puromyocin
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGCATCCGGATCTTGGACCCTTATGTACACTGCTGTATGTTACTCTTACAATTCTGTGCTCTTCTGTGAGTTCAGACTTGGCACCTTATTTTACTTCTGAGCCGCTCTCTGCTGTCCAGAAACTTGGTGGACCTGTAGTACTGCATTGTTCTGCTCAACCTGTGACCACTCGTATCTCATGGCTGCATAACGGAAAAACATTGGATGGAAACCTGGAACATGTTAAGATTCATCAGGGGACTCTGACAATTCTTTCTCTCAACTCCTCTCTTTTGGGTTACTACCAGTGCCTTGCCAACAATAGCATCGGTGCCATTGTGAGTGGCCCTGCGACAGTATCTGTGGCAGTTCTTGGTGATTTTGGTTCATCCACAAAGCATGTTATTACAGCAGAAGAAAAAAGTGCTGGTTTCATTGGCTGCAGGGTACCGGAGAGTAACCCCAAAGCTGAGGTGCGCTATAAAATCCGGGGAAAATGGCTGGAACATTCCACAGAGAATTACTTAATCCTTCCATCAGGAAATCTTCAGATTTTGAATGTATCCTTAGAGGACAAGGGATCATACAAATGTGCAGCTTATAATCCTGTCACACATCAATTAAAAGTTGAACCTATTGGCCGAAAGCTCCTTGTGAGTCGTCCTTCTTCAGATGATGTTCACATTCTTCACCCCACCCATTCACAGGCATTAGCTGTTCTTTCTCGTAGCCCTGTAACCTTGGAGTGTGTGGTGAGTGGGGTCCCGGCTCCTCAAGTGTATTGGCTAAAGGACGGGCAGGACATTGCACCAGGAAGCAACTGGAGAAGGTTGTATTCTCATCTTGCCACTGATAGCGTTGACCCGGCGGACTCCGGAAACTATTCCTGCATGGCGGGAAACAAGTCTGGAGATGTAAAATATGTGACTTACATGGTTAATGTACTTGAACATGCTTCCATTTCTAAAGGACTACAGGATCAGATAGTGTCTCTGGGTGCCACAGTACACTTTACCTGCGACGTTCATGGGAACCCAGCCCCCAACTGTACCTGGTTTCACAATGCACAGCCTATTCATCCTTCTGCACGACATCTAACTGCAGGAAACGGACTGAAAATCAGTGGGGTTACTGTGGAAGATGTTGGGATGTATCAGTGTGTAGCAGATAATGGGATTGGATTTATGCACTCTACTGGAAGACTTGAAATTGAAAATGACGGTGGATTCAAGCCAGTTATAATTACGGCACCAGTAAGTGCAAAGGTTGCAGACGGAGACTTTGTTACTCTGTCCTGCAATGCCAGTGGGCTGCCGGTTCCGGTCATTCGTTGGTATGACAGCCATGGATTGATAACCAGCCATCCATCTCAAGTCCTGAGATCGAAATCCCGAAAATCACAGTTATCAAGACCTGAGGGCTTGAACCTGGAGCCTGTGTACTTCGTCCTGTCCCAAGCTGGTGCAAGCTCTCTCCATATTCAGGCTGTGACTCAGGAACATGCGGGGAAATACATCTGCGAAGCTGCAAATGAACATGGTACCACACAGGCAGAAGCATCTCTCATGGTTGTTCCTTTTGAAACAAATACAAAAGCAGAGACAGTCACACTTCCTGATGCTGCTCAGAATGATGACAGAAGTAAGAGAGATGGTTCAGAAACTGGGTTACTGAGCTCATTTCCGGTGAAGGTCCATCCCAGTGCAGTGGAATCAGCACCAGAGAAAAACGCCAGCGGCATCTCTGTTCCTGATGCCCCCATCATACTGAGCCCCCCACAGACCCACACACCAGACACGTACAACCTGGTGTGGAGGGCAGGCAAGGATGGTGGGCTGCCCATCAATGCTTACTTTGTGAAGTATCGAAAGCTGGATGATGGGGTTGGCATGCTGGGAAGCTGGCACACGGTTCGAGTCCCAGGAAGTGAAAATGAGCTCCATTTAGCTGAGCTGGAGCCATCTAGTCTTTATGAAGTCTTGATGGTAGCAAGAAGCGCAGCAGGTGAAGGCCAACCTGCCATGCTTACCTTCCGAACCAGCAAAGAAAAAACAGCGTCATCAAAAAACACCCAGGCATCCTCTCCACCCGTGGGCATCCCTAAGTATCCCGTTGTTTCAGAGGCTGCAAACAACAATTTTGGAGTGGTACTTACAGATTCCTCTAGGCACAGTGGAGTTCCAGAGGCACCAGATCGGCCTACCATCTCCACTGCATCAGAGACATCAGTCTATGTCACTTGGATTCCTCGGGCAAACGGGGGTTCTCCAATCACTGCCTTCAAAGTCGAATATAAACGGATGAGGACCAGCAATTGGCTGGTGGCAGCTGAAGACATCCCTCCTTCCAAACTTTCAGTGGAAGTTCGTAGTTTAGAACCAGGTTCAACATACAAATTTAGGGTCATTGCCATCAACCATTATGGTGAGAGTTTTCGGAGTTCAGCATCTCGTCCTTATCAAGTGGTTGGGTTCCCCAATCGCTTTTCCAGCCGTCCAATAACTGGACCTCACATTGCATACACAGAGGCTGTCAGCGATACTCAGATCATGCTAAAGTGGACGTACATTCCATCAAGTAACAATAACACTCCCATTCAAGGATTTTATATCTATTACCGACCAACAGATAGTGACAATGACAGTGATTACAAGAGGGATGTTGTAGAAGGTTCAAAGCAGTGGCACATGATTGGCCACCTGCAGCCAGAAACCTCCTATGACATTAAAATGCAATGCTTCAATGAAGGAGGAGAAAGTGAATTTAGCAATGTGATGATCTGCGAGACTAAAGTGAAACGTGTTCCTGGAGCTTCTGAATATCCTGTCAAAGACTTGAGTACCCCTCCAAATTCTTTGGGAAGTGGAGGAAATGTGGGGCCTGCAACCAGCCCTGCCAGAAGCAGTGACATGTTATATCTGATCGTTGGCTGTGTGCTGGGCGTCATGGTCCTCATTCTGATGGTTTTCATTGCAATGTGCCTGTGGAAGAATCGCCAGCAGAATACCATACAAAAATATGACCCACCAGGATATCTCTACCAAGGATCAGATATGAACGGGCAGATGGTGGACTACACCACTCTCTCAGGAGCAAGTCAGATAAATGGAAATGTTCACGGAGGCTTCCTAACCAATGGCGGTCTCAGCAGTGGCTATTCCCACCTTCACCATAAGGTCCCCAATGCAGTCAATGGAATTGTGAATGGGAGCCTAAATGGAGGGCTTTACTCCGGGCACAGCAACTCTCTAACCAGGACACACGTGGATTTTGAACATCCTCATCATCTAGTGAATGGTGGTGGAATGTACACGGCCGTGCCTCAGATTGACCCTCTGGAGTGTGTTAACTGCCGAAATTGTCGAAACAACAATAGGTGTTTCACCAAAACCAACAGCACTTTCAGCAGCAGCCCTCCTCCTGTGGTCCCTGTGGTAGCACCTTATCCTCAGGATGGTTTGGAAATGAAGCCCCTCAGTCACGTGAAGGTGCCTGTATGCCTGACTTCCGCAGTCCCTGATTGTGGCCAGTTGCCGGAGGAGAGCGTCAAGGACAATGTGGAACCAGTCCCTACTCAGCGTACCTGCTGTCAGGACATTGTAAATGACGTCAGCTCTGATGGCTCAGAAGATCCAGCAGAGTTCAGCAGAGGTCAGGAAGGCATGATCAACCTTAGGATTCCAGATCATCTTCAGTTAGCTAAGAGCTGTGTATGGGAAGGAGACAGCTGTGCCCATTCAGAAACAGAGATCAACATTGTAAGTTGGAATGCTCTTATTTTGCCACCTGTCCCCGAGGGCTGTGCTGAGAAGACAATGTGGTCTCCACCTGGCATTCCTTTAGACAGCCCGACAGAGGTCCTTCAGCAGCCCCGGGAAACCTGA
ORF Protein Sequence MHPDLGPLCTLLYVTLTILCSSVSSDLAPYFTSEPLSAVQKLGGPVVLHCSAQPVTTRISWLHNGKTLDGNLEHVKIHQGTLTILSLNSSLLGYYQCLANNSIGAIVSGPATVSVAVLGDFGSSTKHVITAEEKSAGFIGCRVPESNPKAEVRYKIRGKWLEHSTENYLILPSGNLQILNVSLEDKGSYKCAAYNPVTHQLKVEPIGRKLLVSRPSSDDVHILHPTHSQALAVLSRSPVTLECVVSGVPAPQVYWLKDGQDIAPGSNWRRLYSHLATDSVDPADSGNYSCMAGNKSGDVKYVTYMVNVLEHASISKGLQDQIVSLGATVHFTCDVHGNPAPNCTWFHNAQPIHPSARHLTAGNGLKISGVTVEDVGMYQCVADNGIGFMHSTGRLEIENDGGFKPVIITAPVSAKVADGDFVTLSCNASGLPVPVIRWYDSHGLITSHPSQVLRSKSRKSQLSRPEGLNLEPVYFVLSQAGASSLHIQAVTQEHAGKYICEAANEHGTTQAEASLMVVPFETNTKAETVTLPDAAQNDDRSKRDGSETGLLSSFPVKVHPSAVESAPEKNASGISVPDAPIILSPPQTHTPDTYNLVWRAGKDGGLPINAYFVKYRKLDDGVGMLGSWHTVRVPGSENELHLAELEPSSLYEVLMVARSAAGEGQPAMLTFRTSKEKTASSKNTQASSPPVGIPKYPVVSEAANNNFGVVLTDSSRHSGVPEAPDRPTISTASETSVYVTWIPRANGGSPITAFKVEYKRMRTSNWLVAAEDIPPSKLSVEVRSLEPGSTYKFRVIAINHYGESFRSSASRPYQVVGFPNRFSSRPITGPHIAYTEAVSDTQIMLKWTYIPSSNNNTPIQGFYIYYRPTDSDNDSDYKRDVVEGSKQWHMIGHLQPETSYDIKMQCFNEGGESEFSNVMICETKVKRVPGASEYPVKDLSTPPNSLGSGGNVGPATSPARSSDMLYLIVGCVLGVMVLILMVFIAMCLWKNRQQNTIQKYDPPGYLYQGSDMNGQMVDYTTLSGASQINGNVHGGFLTNGGLSSGYSHLHHKVPNAVNGIVNGSLNGGLYSGHSNSLTRTHVDFEHPHHLVNGGGMYTAVPQIDPLECVNCRNCRNNNRCFTKTNSTFSSSPPPVVPVVAPYPQDGLEMKPLSHVKVPVCLTSAVPDCGQLPEESVKDNVEPVPTQRTCCQDIVNDVSSDGSEDPAEFSRGQEGMINLRIPDHLQLAKSCVWEGDSCAHSETEINIVSWNALILPPVPEGCAEKTMWSPPGIPLDSPTEVLQQPRET

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-MP0245-Ab Anti-CDON/ CDO1/ HPE11 monoclonal antibody
    Target Antigen GM-Tg-g-MP0245-Ag CDON VLP (virus-like particle)
    ORF Viral Vector pGMLP-SPh-080 Human CDON Lentivirus plasmid
    ORF Viral Vector pGMAP-SPh-220 Human CDON Adenovirus plasmid
    ORF Viral Vector vGMLP-SPh-080 Human CDON Lentivirus particle
    ORF Viral Vector vGMAP-SPh-220 Human CDON Adenovirus particle


    Target information

    Target ID GM-MP0245
    Target Name CDON
    Gene ID 50937, 57810, 714039, 50938, 101087264, 489296, 536011, 100064474
    Gene Symbol and Synonyms Cd0,CDO,CDON,CDON1,HPE11,Ihog,ORCAM
    Uniprot Accession Q4KMG0
    Uniprot Entry Name CDON_HUMAN
    Protein Sub-location Transmembrane Protein
    Category Not Available
    Disease Not Available
    Gene Ensembl ENSG00000064309
    Target Classification Not Available

    This gene encodes a cell surface receptor that is a member of the immunoglobulin superfamily. The encoded protein contains three fibronectin type III domains and five immunoglobulin-like C2-type domains. This protein is a member of a cell-surface receptor complex that mediates cell-cell interactions between muscle precursor cells and positively regulates myogenesis. [provided by RefSeq, Aug 2011]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.